JP2015502958A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502958A5
JP2015502958A5 JP2014546103A JP2014546103A JP2015502958A5 JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5 JP 2014546103 A JP2014546103 A JP 2014546103A JP 2014546103 A JP2014546103 A JP 2014546103A JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5
Authority
JP
Japan
Prior art keywords
subject
effective amount
therapeutically effective
pathway inhibitor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014546103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/068351 external-priority patent/WO2013086260A2/en
Publication of JP2015502958A publication Critical patent/JP2015502958A/ja
Publication of JP2015502958A5 publication Critical patent/JP2015502958A5/ja
Pending legal-status Critical Current

Links

JP2014546103A 2011-12-09 2012-12-07 がんの処置のための併用療法 Pending JP2015502958A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161568844P 2011-12-09 2011-12-09
US61/568,844 2011-12-09
US201261698030P 2012-09-07 2012-09-07
US61/698,030 2012-09-07
PCT/US2012/068351 WO2013086260A2 (en) 2011-12-09 2012-12-07 Combination therapy for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2015502958A JP2015502958A (ja) 2015-01-29
JP2015502958A5 true JP2015502958A5 (enExample) 2016-02-04

Family

ID=48575059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546103A Pending JP2015502958A (ja) 2011-12-09 2012-12-07 がんの処置のための併用療法

Country Status (4)

Country Link
US (1) US20150132301A1 (enExample)
EP (1) EP2788378A4 (enExample)
JP (1) JP2015502958A (enExample)
WO (1) WO2013086260A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
WO2015009851A1 (en) * 2013-07-16 2015-01-22 Icahn School Of Medicine At Mount Sinai Methods of treating cancer in subjects afflicted with metabolic dysfunction
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
HK1223657A1 (zh) * 2013-12-02 2017-08-04 Oncomed Pharmaceuticals, Inc. 與wnt途徑抑制劑有關的預測性生物標記物的鑒別
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP2975047A1 (en) * 2014-07-18 2016-01-20 Université de Lausanne Wnt7a polypeptides and their use
WO2017040666A2 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
WO2018170485A1 (en) * 2017-03-16 2018-09-20 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic and therapeutic methods for kras positive cancers
CN107441045B (zh) * 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CA3227706A1 (en) * 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230383360A1 (en) * 2021-12-16 2023-11-30 D2G Oncology, Inc. Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142481A0 (en) * 2001-04-05 2002-03-10 Yissum Res Dev Co A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
KR20080101888A (ko) * 2006-02-09 2008-11-21 다이이찌 산쿄 가부시키가이샤 항암 의약 조성물
CN101541977A (zh) * 2006-09-19 2009-09-23 诺瓦提斯公司 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
JP5363350B2 (ja) * 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
US20090082328A1 (en) * 2007-05-11 2009-03-26 Bayer Schering Pharma Aktiengesellschaft Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
WO2008157179A2 (en) * 2007-06-12 2008-12-24 Genentech, Inc. N-substituted azaindoles and methods of use
KR20100049073A (ko) * 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
JP2010535232A (ja) * 2007-07-30 2010-11-18 アルディア バイオサイエンス，インク． Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
CA2924436A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
US20100267626A1 (en) * 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
CA2705452C (en) * 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
ES2663536T3 (es) * 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agentes que se unen a receptores frizzled y usos de los mismos
AU2010224044A1 (en) * 2009-03-11 2011-09-22 Ardea Biosciences, Inc. Pharmaceutical combinations comprising RDEA119/BAY 869766 for the treatment of specific cancers
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CN103038364A (zh) * 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
CN102971337B (zh) * 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US20120231965A1 (en) * 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
PL2672967T3 (pl) * 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu

Similar Documents

Publication Publication Date Title
JP2015502958A5 (enExample)
IL267609B (en) Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
HUE036583T2 (hu) Notch jelzõ folyamat inhibitorai és alkalmazásuk rákok kezelésében
HUE040044T2 (hu) Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
PL3489261T3 (pl) Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
IL243976A0 (en) kdm1a inhibitors for disease treatment
WO2015003360A3 (en) Therapeutically active compounds and their methods of use
IL232128A0 (en) Cancer treatment with inhibitors if tor kinase inhibitors
IL228538A0 (en) Methods for increasing efficacy of folr1 cancer therapy
HK1216175A1 (zh) 治療性化合物和組合物
EP3065549A4 (en) Methods for inhibiting tie2 kinase useful in the treatment of cancer
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
PL3004108T3 (pl) Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
SI2945642T1 (sl) Protein faktorja 1 za uporabo pri zdravljenju ali preprečevanju bolezni
ZA201406708B (en) Treatment of cancer with tor kinase inhibitors
IL234602A0 (en) Cancer treatment with rapamycin target site kinase inhibitors
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
ZA201607740B (en) Treatment of the complications of chronic liver disease with caspase inhibitors
PL3456333T3 (pl) Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego
IL234641B (en) Cancer treatment with rapamycin target site kinase inhibitors
HK1223924A1 (zh) 治疗活性化合物及其使用方法
EP3050884A4 (en) Novel chemical compounds (variants) and the use thereof to treat oncological diseases